Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | ACP1 | P24666 | 5/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295442 | 1.00 | LMNA (0.49) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295632 | 0.90 | LMNA (0.57) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295631 | 0.90 | LMNA (0.57) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295285 | 0.90 | ALDH1A1 (0.49) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295287 | 0.90 | ALDH1A1 (0.49) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295405 | 0.89 | CA9 (0.60) | CA9CA2PTPN1ACP1 | |
| SCHEMBL17295403 | 0.89 | CA9 (0.60) | CA9CA2PTPN1ACP1 | |
| SCHEMBL17295378 | 0.84 | MAPT (0.51) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295392 | 0.84 | PTPN1 (0.51) | LMNAHPGDSMN1; SMN2CA9CA2 | |
| SCHEMBL17295389 | 0.84 | PTPN1 (0.51) | LMNAHPGDSMN1; SMN2CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148990-B1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-10774077-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2020-09-15 | — | — | US | disclosed |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2019-04-25 | — | — | US | disclosed |
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2018-12-18 | — | — | US | disclosed |
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3148990-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181337-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | LMNA 4277/4885HPGD 1946/4885SMN1; SMN2 3070/4885 |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | LMNA 4207/4885HPGD 1206/4885SMN1; SMN2 3401/4885 |
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | LMNA 4265/4885HPGD 1995/4885SMN1; SMN2 3103/4885 |
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | LMNA 4207/4885HPGD 1206/4885SMN1; SMN2 3401/4885 |
| US-10774077-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | LMNA 4207/4885HPGD 1206/4885SMN1; SMN2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.